Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab vs TACE for HCC with PVTT After Resection
NCT03914352Unknown
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Randomised, open-label trial of camrelizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoints: Overall Survival at 5 years and Disease-Free Survival at 5 years. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03914352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03914352.